Cerebellopontine Angle Schwannomas: Surgery, Hypofractionated Stereotactic Radiotherapy, Combined Therapy. Strategy for Harmless Therapy

• Published in: Journal of Neurological Surgery Part B: Skull Base Vol. 73; no. S 02
• Main Authors: Lecce, M., Fraioli, C., Umana, G., Giovinazzo, G., Novegno, F., Fraioli, M. F.
• Format: Conference Proceeding Journal Article
• Language: English
• Published: 01.06.2012
• ISSN: 2193-6331; 2193-634X
• DOI: 10.1055/s-0032-1314131

Objective: The pontocerebellar angle schwannomas represent a neurosurgical challenge because after radical removal important neurological deficits can result. Design: To evaluate the best therapy concerning control of tumoral evolution and functional outcome. Methods: A series of 13 vestibular schwannomas and 3 Gasserian ganglion schwannomas is presented. According to the size, three were defined as small (maximum extrameatal diameter 2 cm), eight tumors were classified as large (diameter 2.5 to 4 cm), and the last five tumors were defined as giant (diameter 4.5 to 6 cm). Thirteen patients underwent the retrosigmoid microsurgical approach, followed by hypofractionated stereotactic radiotherapy (HSRT) in 11 of the patients. Intraoperative brainstem-evoked potentials and monitoring of facial nerve were done. Two other tumors were submitted to HSRT alone. The last one was submitted to seriated controls. Results: Gross total removal (postoperative tumor remnant less than 1 cm of maximum diameter) was achieved in 10 patients; subtotal removal (postoperative remnant 1 to 2 cm) was performed in the other three patients. After surgery, worsening of a preoperative facial nerve paresis occurred in one patient operated on (gross total removal) for a giant tumor. After HSRT alone, temporary paucisymptomatic hydrocephalus occurred in one patient, treated by low-dose betamethasone and diuretics. Hearing function was preserved in all patients. Conclusions: Our results showed that for symptomatic schwannomas, gross total removal followed by HSRT is a valid therapeutic strategy, allowing improved symptoms and avoiding tumor recurrence with very a low rate of neurological deficit.